ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO1134

Patient-Reported Health Status of Adults with Kidney Failure Receiving Hemodiafiltration vs. Hemodialysis: Results from the CONVINCE Randomized Controlled Clinical Trial

Session Information

  • Late-Breaking Posters
    November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Rose, Matthias, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Fischer, Felix, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Liegl, Gregor, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Strippoli, Giovanni, Universita degli Studi di Bari Aldo Moro, Bari, Puglia, Italy
  • Hockham, Carinna, The George Institute for Global Health, School of Public Health, Imperial College London, London, United Kingdom
  • Vernooij, Robin W.m., Universiteit Utrecht, Utrecht, Utrecht, Netherlands
  • Barth, Claudia Maria, B. Braun Avitum AG, Melsungen, Germany
  • Canaud, Bernard J., MTX Consulting, Montpellier, France
  • Covic, Adrian, University of Medicine "Grigore T. Popa", Bucharest, Romania
  • Cromm, Krister, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Hessen, Germany
  • Davenport, Andrew, University College London, London, United Kingdom
  • Fischer, Kathrin Irmgard, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Hegbrant, Jorgen BA, JBA Medical AB, Bjarred, Sweden
  • Jaha, Hanna, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Schappert, Anna, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Török, Marietta, Diaverum AB, Malmo, Skåne, Sweden
  • Bots, Michiel L., Universiteit Utrecht, Utrecht, Utrecht, Netherlands
  • Blankestijn, Peter J., University Medical Center Utrecht, Utrecht, Netherlands

Group or Team Name

  • For the CONVINCE Scientific Committee and Investigators
Background

The CONVINCE trial showed a significant survival benefit for patients receiving high-dose hemodiafiltration as compared with conventional high-flux hemodialysis (N Engl J Med 2023; 389:700-709). A further objective was to compare the patient-reported health status between both interventions.

Methods

The CONVINCE Trial is multi-center, prospective randomized, open label, controlled trial, comparing benefits and safety of high-dose hemodiafiltration (HDF) versus high-flux hemodialysis (HD). The perceived health status was assessed in eight domains (physical function, cognitive function, fatigue, sleep disturbance, depression, anxiety, pain interference, social participation) using instruments from the Patient-Reported Outcome Measurement Information System PROMIS® before randomization and every three-month after over three years. The main analyses compared the mean change from baseline using an omnibus test for all eight domains, and a Linear Mixed Model to identify group x time interaction effects for specific domains.

Results

1,360 patients have been enrolled, 677 receiving hemodialysis and 683 hemodiafiltration, with a median observation time of 30 month. For 84% of all treated patients PRO assessments could be analyzed (10,681 questionnaires). On average patients described statistically significant health deteriorations in all domains, with most pronounced declines in physical function scores. Potential group differences between HDF vs HD will be disclosed at the ASN Congress.

Conclusion

As of today, the CONVINCE trial has applied the most comprehensive assessment of PROs within a large RCT comparing HDF with HD, deepening the understanding of the determining factors of perceived health of patients receiving renal replacement therapies. The relevance of potential group differences will be discussed at the conference.

Funding

  • Government Support - Non-U.S.